Dar Zavain 4

What Happened

• Dar Zavain, a director of Recursion Pharmaceuticals (RXRX), was granted 88,424 restricted stock units (RSUs) on June 17, 2026. The Form 4 reports an acquisition price of $0.00 because this was a compensation grant, not an open‑market purchase or sale. The RSUs convert to shares only upon vesting and do not represent immediately tradeable stock.

Key Details

• Transaction date: 2026-06-17; Form 4 filed: 2026-06-22 (filed more than 2 business days after the grant date).
• Grant: 88,424 RSUs; reported price per share: $0.00 (award/grant).
• Vesting: RSUs vest on the earlier of June 17, 2027 or the day before the Issuer’s 2027 Annual Meeting of Stockholders, subject to continued service (footnote F1).
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• No indication of a 10b5-1 plan, option exercise, sale, gift, or tax withholding reported in the supplied details.

Context

• RSU grants to outside directors are common compensation and are generally routine rather than a direct market signal. Because these RSUs vest in the future, they do not represent immediately sellable shares. The Form 4 was filed several days after the grant (Form 4s are typically required within 2 business days), which investors may note as a timeliness issue.